Self Amplifying RNA Vaccines Patent Landscape and Forecast Report 2024-2032, Featuring Gentech, Novartis, Human Genome Sciences, Immatics Biotechnologies and Broad Institute [Yahoo! Financ...
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The self amplifying RNA vaccines market was valued at USD 5.8 billion in 2023 and is projected to reach USD 13.1 million by 2032, growing at a CAGR of 9.6% from 2024-2032. The patent landscape for self-amplifying RNA (saRNA) vaccines is dynamic, with the United States leading in filings. It holds over 200 patents focused on novel delivery systems, RNA stability, and immunogenicity enhancements. Approximately 50 new patents were filed in the past year, underscoring ongoing innovation. Future growth is expected to be driven by advancements in AI for vaccine design and improved lipid nanoparticle formulations. This report offers an in-depth analysis of the global self-amplifying RNA vaccines patent landscape. It explores industry size, regional patent activity, and segmentation by type, administration route, and therapeutic area. Highlighting key innovations in RNA stability and del
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics [Yahoo! Finance]Yahoo! Finance
- Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Novartis acquires Kate Therapeutics to advance gene therapies [Yahoo! Finance]Yahoo! Finance
- Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director [Yahoo! Finance]Yahoo! Finance
- Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential' will drive long-term growth [Fortune]Fortune
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- 9/18/24 - Form 6-K
- NVS's page on the SEC website